symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
XRTX,0.281,0.18759,71176,5055106,0.375,0.25-1.24,-0.0217,XORTX Therapeutics Inc.,USD,0001729214,CA98420Q2071,98420Q207,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.xortx.com,"XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.",Dr. Allen Warren Davidoff Ph.D.,Healthcare,CA,3,,421 â€“ 7th Avenue SW,Vancouver,BC,T2P 4K9,,0,https://financialmodelingprep.com/image-stock/XRTX.png,2021-09-23,False,False,True,False,False
